- Home
- ICLR vs INCY Comparison
ICLR vs INCY Comparison
Compare ICLR & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICLR
- INCY
- Stock Information
- Founded
- ICLR 1990
- INCY 1991
- Country
- ICLR Ireland
- INCY United States
- Employees
- ICLR N/A
- INCY N/A
- Industry
- ICLR Biotechnology: Commercial Physical & Biological Resarch
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- ICLR Health Care
- INCY Health Care
- Exchange
- ICLR Nasdaq
- INCY Nasdaq
- Market Cap
- ICLR 14.5B
- INCY 13.0B
- IPO Year
- ICLR 1998
- INCY 1993
- Fundamental
- Price
- ICLR $167.41
- INCY $77.34
- Analyst Decision
- ICLR Buy
- INCY Hold
- Analyst Count
- ICLR 13
- INCY 20
- Target Price
- ICLR $211.92
- INCY $77.69
- AVG Volume (30 Days)
- ICLR 1.7M
- INCY 1.6M
- Earning Date
- ICLR 07-23-2025
- INCY 07-29-2025
- Dividend Yield
- ICLR N/A
- INCY N/A
- EPS Growth
- ICLR 13.11
- INCY 900.04
- EPS
- ICLR 9.73
- INCY 4.37
- Revenue
- ICLR $8,089,820,000.00
- INCY $4,584,996,000.00
- Revenue This Year
- ICLR N/A
- INCY $13.53
- Revenue Next Year
- ICLR $1.72
- INCY $10.38
- P/E Ratio
- ICLR $17.10
- INCY $17.87
- Revenue Growth
- ICLR N/A
- INCY 18.87
- 52 Week Low
- ICLR $125.10
- INCY $53.56
- 52 Week High
- ICLR $328.35
- INCY $83.95
- Technical
- Relative Strength Index (RSI)
- ICLR 53.53
- INCY 68.49
- Support Level
- ICLR $162.99
- INCY $73.81
- Resistance Level
- ICLR $211.00
- INCY $78.77
- Average True Range (ATR)
- ICLR 8.03
- INCY 1.98
- MACD
- ICLR -0.78
- INCY 0.79
- Stochastic Oscillator
- ICLR 38.22
- INCY 94.91
About ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.